Organogenesis
Massachusetts, United States · Biotechnology, Health Care, Manufacturing · 1,000 employees
Organogenesis™ is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.
Funding history
- Funding Round — $130.0M — Nov 2024
Recent signals
- Dec 29, 2025: Organogenesis Holdings Inc. Amends Lease Agreements for Manufacturing Facilities
- Dec 22, 2025: SEC 8-K (1.01): On December 22, 2025, Organogenesis Inc. entered into two significant lease amendments - one with 65 Dan Road SPE, LLC for the premises at 65 Dan Road, and another with Dan Road Associates, LLC for the premises at 150 Dan Road, both located in Canton, Massachusetts. These amendments extend the lease terms from December 31, 2027, to December 31, 2032, securing the space for Organogenesis' manufacturing, shipping, operations, and research and development activities. This strategic move bolsters the Company's operational capabilities and long-term planning within its headquarters. The amendments enhance lease terms, ensuring stability in key operational locations for an additional five years.
- Nov 27, 2024: Raised $130.0M
- Nov 11, 2024: Launched Organogenesis Holdings Inc. announces positive interim analysis results for ReNu, a treatment for knee osteoarthritis.
See plans & pricing → Track Organogenesis’s funding, hiring, and signals — with verified contacts — on Fundz.